M Bacchi
Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment
Sabbioni M, Goldhirsch A, Herrmann R, Perey L, Bonnefoi H, Thürlimann B, Castiglione M, Bernhard J, Bacchi M, Siegrist H, Hürny C. Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment. Breast cancer research and treatment 2000; 59:279-87.
Feb 1, 2000Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment
Feb 1, 2000Breast cancer research and treatment 2000; 59:279-87
Sabbioni M E, Goldhirsch A, Herrmann R, Perey L, Bonnefoi H, Thürlimann Beat, Castiglione M, Bernhard J, Bacchi M, Siegrist H P, Hürny C
Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients
Sabbioni M, Goldhirsch A, Perey L, Bonnefoi H, Thürlimann B, Bernhard J, Bacchi M, Siegrist H, Hürny C, Castiglione M, Senn H. Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999; 7:149-53.
May 1, 1999Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients
May 1, 1999Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999; 7:149-53
Sabbioni M E, Goldhirsch A, Perey L, Bonnefoi H, Thürlimann Beat, Bernhard J, Bacchi M, Siegrist H P, Hürny C, Castiglione M, Senn H J
The cognitive-spiritual dimension--an important addition to the assessment of quality of life: validation of a questionnaire (SELT-M) in patients with advanced cancer
Van Wegberg B, Castiglione M, Hürny C, Bernhard J, Von Rohr E, Schaad R, Helwig S, Heusser P, Bacchi M, Cerny T. The cognitive-spiritual dimension--an important addition to the assessment of quality of life: validation of a questionnaire (SELT-M) in patients with advanced cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998; 9:1091-6.
Oct 1, 1998The cognitive-spiritual dimension--an important addition to the assessment of quality of life: validation of a questionnaire (SELT-M) in patients with advanced cancer
Oct 1, 1998Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998; 9:1091-6
Van Wegberg B, Castiglione M, Hürny C, Bernhard J, Von Rohr E, Schaad R, Helwig S, Heusser P, Bacchi M, Cerny Thomas
Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials
Hürny C, Van Wegberg B, Bacchi M, Bernhard J, Thürlimann B, Real O, Perey L, Bonnefoi H, Coates A. Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials. British journal of cancer 1998; 77:985-91.
Mar 1, 1998Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials
Mar 1, 1998British journal of cancer 1998; 77:985-91
Hürny C, Van Wegberg B, Bacchi M, Bernhard J, Thürlimann Beat, Real O, Perey L, Bonnefoi H, Coates A
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88
Thürlimann B, Fey M, Senn H, Cavalli F, Jungi W, Goldhirsch A, Castiglione-Gertsch M, Bacchi M, Beretta K, Löhnert T. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996; 7:471-9.
Jul 1, 1996First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88
Jul 1, 1996Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996; 7:471-9
Thürlimann Beat, Fey M, Senn H J, Cavalli F, Jungi W F, Goldhirsch A, Castiglione-Gertsch M, Bacchi M, Beretta K, Löhnert T
Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK)
Joss R, Stahel R, Martinelli G, Cerny T, Thürlimann B, Leyvraz S, Bacchi M, Hürny C, Alberto P, Ludwig C. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995; 6:41-8.
Jan 1, 1995Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK)
Jan 1, 1995Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995; 6:41-8
Joss R A, Stahel R, Martinelli G, Cerny T, Thürlimann Beat, Leyvraz S, Bacchi M, Hürny C, Alberto P, Ludwig C
First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research
Borner M, Cavalli F, Thürlimann B, Jungi W, Castiglione M, Harder F, Greiner R, Goldhirsch A, Bacchi M, Obrecht J. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. J Clin Oncol 1994; 12:2071-7.
Oct 1, 1994First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research
Oct 1, 1994J Clin Oncol 1994; 12:2071-7
Borner M, Cavalli F, Thürlimann Beat, Jungi W F, Castiglione M, Harder F, Greiner R, Goldhirsch A, Bacchi M, Obrecht J P
Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK)
Joss R, Bacchi M, Buser K, Kirchner V, Neuenschwander H, Orth B, Aapro M, Thürlimann B. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1994; 5:253-8.
Mar 1, 1994Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK)
Mar 1, 1994Ann Oncol 1994; 5:253-8
Joss R A, Bacchi M, Buser K, Kirchner V, Neuenschwander H, Orth B, Aapro M S, Thürlimann Beat